Clinical trials: Relapsed/Refractory Acute Myeloid Leukemia (AML), open to volunteers
IDH1 Mutation, Relapsed / Refractory AML
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
This is a prospective, single-arm phase 2 pilot study to assess the response rate of IDH1 mutated relapsed/refractory acute myeloid leukemia (AML) patients who receive olutasidenib after progressing on venetoclax based regimens.
- Trial name
- NCT07471841
- Testing
- Olutasidenib, Azacitidine (AZA)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Timothy Pardee
Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
CLN-049-001 is a Phase 1/2, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), TP53-mutated MDS and AML
- Trial name
- NCT05143996
- Testing
- CLN-049
- Where
- 17 sites in United States
- Volunteers
- 275 people
- Sponsor
- Cullinan Therapeutics Inc.
Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia
CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia
This is a single-center, open-label, single-arm, prospective, investigator-initiated dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an autologous CLL-1/CD70 dual-target CAR-T cell…
- Trial name
- NCT07897136
- Testing
- CLL-1-CD70 CAR-T Cell Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Liping Dou
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescents with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has come back after treatment…
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric Cancer
- Trial name
- NCT07770698
- Testing
- sonrotoclax, Azacitidine, Inotuzumab ozogamicin
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myeloid Leukemia (AML)
CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML
This is a Phase 1, open label, dose-escalation study to evaluate the safety, expansion, persistence, and preliminary clinical activity of lentivirally transduced autologous T cells expressing anti-CD64 chimeric antigen receptors…
- Conditions
- Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, AML (Acute Myeloid Leukemia)
- Trial name
- NCT07347418
- Testing
- CD64 CAR T Cells
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Colorado, Denver
Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML)
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703…
- Conditions
- Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Relapsed/Refractory AML, Relapsed Myelodysplastic Syndromes
- Trial name
- NCT06846606
- Testing
- AUTX-703
- Where
- 9 sites in United States
- Volunteers
- 69 people
- Sponsor
- Auron Therapeutics, Inc.
AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of WBC100 capsules in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
- Conditions
- AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia, Refractory Acute Myeloid Leukemia, Hematologic Malignancy
- Trial name
- NCT07014449
- Testing
- WBC100 QD
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Hangzhou Weben Pharma Co., Ltd
Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia
This is a single-arm, single-center clinical study to assess the efficacy and safety of Mitoxantrone Hydrochloride Liposome combined with cladribine and sotoraclib in patients with relapsed/refractory acute myeloid leukemia…
- Trial name
- NCT07874737
- Testing
- Mitoxantrone Hydrochloride Liposome+cladribine+sotoraclib
- Volunteers
- 20 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
KMT2A-rearranged, NPM1-mutant Refractory or Relapsed AML
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with either KMT2A-rearranged (KMT2A-r) or NPM1-mutant relapsed or refractory…
- Trial name
- NCT07355335
- Testing
- Ziftomenib, Mezigdomide
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Individualized AML Treatment
Every patient responds differently to their cancer treatment, and some treatments work better for some patients more than others.
- Trial name
- NCT07613385
- Testing
- Observational
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Relapsed/Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML)
CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia
This is a single-center, open-label, single-arm, phase 1 dose-escalation study to evaluate the safety, tolerability, preliminary efficacy, and cellular kinetics of SL1CC Injection, an in vivo CAR-T therapy targeting CLL-1, in…
- Trial name
- NCT07841002
- Testing
- SL1CC Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Liping Dou
Relapsed / Refractory AML, High Risk Myelodysplastic Syndrome
Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN
This is a single-center randomized phase 2 open-label clinical trial.
- Conditions
- Relapsed / Refractory AML, High Risk Myelodysplastic Syndrome, High Risk Myeloproliferative Neoplasms
- Trial name
- NCT07710534
- Testing
- Decitabine-cedazuridine plus venetoclax (DEC-C+VEN), Azacitidine plus venetoclax (AZA+VEN)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Virginia Commonwealth University
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
This is a phase 1 dose escalation study to determine the safety of anti-FLT3 CAR-T in subjects with R/R AML. The primary objective is to assess safety.
- Trial name
- NCT06786533
- Testing
- Anti-FLT3 CAR-T cells
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Hemogenyx Pharmaceuticals LLC
Relapsed/Refractory Acute Myeloid Leukemia (AML)
A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
This is a single-arm, open-label, dose-escalation, prospective exploratory clinical study intended to evaluate the safety, efficacy and cellular pharmacokinetics of GT737 cells in adult patients with relapsed/refractory acute…
- Trial name
- NCT07676006
- Testing
- GT737 Injection
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Grit Biotechnology
Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
HPB-092 effectively inhibits Fms-like tyrosine kinase 3 (FLT3) mutants with comparable or superior potency to approved FLT3 inhibitors and demonstrates improved selectivity, potentially reducing toxicity.
- Trial name
- NCT07137637
- Testing
- HPB-092 tablet
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hangzhou Polymed Biopharmaceuticals, Inc.
Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia
Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia
Relapsed or refractory acute leukemia (R/R AL) is a life-threatening blood cancer with poor outcomes and limited treatment options.
- Conditions
- Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Trial name
- R/R AL (NCT07696481)
- Testing
- PID23 Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Zhujiang Hospital
Relapsed or Refractory AML and Other Hematologic Malignancies
Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.
This is the first in human study of KK2845. This clinical trial consists of Part 1 (Dose Escalation) and Part 2 (Backfill). For patients with relapsed or refractory acute myeloid leukemia (AML) and other Hematologic Malignancies…
- Trial name
- NCT06812104
- Testing
- KK2845_1, KK2845_2, KK2845_3
- Where
- 17 sites in Japan
- Volunteers
- 156 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation.
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
- Trial name
- NCT02074839
- Testing
- AG-120
- Where
- 30 sites in United States, France
- Volunteers
- 291 people
- Sponsor
- Institut de Recherches Internationales Servier
Relapsed Adult AML, Refractory AML
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
This is a multi-institutional Phase I/II study of an allogeneic KIR-HLA mismatched NK cell infusion (AdaptNK) and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting chemotherapy…
- Conditions
- Relapsed Adult AML, Refractory AML, Acute Myelogenous Leukemia
- Trial name
- NCT07591649
- Testing
- AdaptNK, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia
Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML
This is a prospective, single-center, observational study to evaluate the efficacy and safety of salvage haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) combined with post-transplant relapse…
- Conditions
- Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, AML, Relapsed/Refractory
- Trial name
- NCT07572695
- Testing
- Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT), Post-transplant Maintenance Therapy
- Volunteers
- 40 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology